Salutary Effects Help ENTB in Other Areas
I agree. When a biomed/tech company can demonstrate that it's able to apply a so-called "off-shelf" solution to other areas, a great deal of capital tends to migrate towards that company. There are good reasons for this is so, including the fact that very little in the way of resources will be needed for research and development.
When the R&D budget isn't impacted by the need to spend large amounts of money on developing secondary uses for a tech company's product it adds to the strength of the bottom line. More capital's available for other things, in other words. Like maybe a dividend, eventually (haha!).
But seriously, having a bottom line that'll be improved by a better cash position (cash that isn't going to improve or modify a product for other important uses) is sure to attract partners or increased amounts of capital investment. The ability to augment stem cell therapies is an exciting, untapped field of endeavor for many biomed companies. It's good to see that ENTB is being aggressive in promoting that aspect.
I also like that the company gained steadily again. That's a nice improvement from its close on the 22nd, to be honest. I figured maybe 1.83 but 1.85 was nice and a lot of money can be made on the margin if one's willing to time it properly. I'm more inclined, though, to ride it a bit longer. I actually think it can hit its 52-week high in the not-too-distant future if it can keep reporting these kinds of advances.
News 
Market Data 
Discover 
